Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

Vitreomacular adhesion is also associated with a much poorer prognosis in certain major eye conditions, including diabetic retinopathy and Age-related Macular Degeneration (AMD).

The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion after one month. This anatomical endpoint is being measured and recorded using optical coherence tomography (OCT) which provides images that can clearly show the separation of the vitreous from the retina. OCT is a very sensitive and specific method for detecting the resolution of focal vitreomacular adhesion. ThromboGenics has used both OCT and ultrasound technology in previous studies evaluating microplasmin in eye disease. Based on this experience and discussions with the FDA, OCT was selected as the main assessment technique for the Phase III program as it provides results which have greater clinical relevance. In addition to the primary endpoint, the Phase III trials will evaluate additional measures of efficacy as well as safety, assessed at various time periods over the six month study period.

It is expected that the results from the TG-MV-006 study will be presented by mid 2010.

Dr. Patrik De Haes, CEO of ThromboGenics commented, "We are very pleased to announce that we have completed enrolment of the US pivotal Phase III trial for microplasmin months ahead of schedule. Microplasmin is key to the success of our ophthalmic focused strategy and the speed at which patients have been recruited is very encouraging. Today's announcement brings us a step closer to potentially changing the way a number of important eye conditions are treated, as well as bringing us closer to our key aim of becoming a profitable, integrated business focused on cutting edge ophthalmic medicines. We very much look forward to announcing the results of this trial by the middle of next year and I am confident that ThromboGenics will continue to deliv
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013  Sinovac Biotech Ltd. (NASDAQ: ... in China , announced that ... Sinovac, obtained the Certificate of Good Manufacturing Practices ... State and Food Administration (CFDA) for its proprietary ... its Changping filing and packaging facility. The GMP ...
(Date:5/23/2013)... 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... 2013 Life Science Firm of the Year by the Tech ... honored at the TCM,s 25 th Annual Tech Awards ... Tech Awards Celebration recognizes the leaders and innovators in the ... and the surrounding regions. "We are ...
(Date:5/23/2013)... May 23, 2013  Haemonetics Corporation (NYSE: HAE ... CFO & EVP-Business Development, will present at The Deutsche Bank ... Boston, MA on May 29, 2013 at ... ) The public may access Mr. Lindop,s presentation ... About Haemonetics Haemonetics (NYSE: HAE ) ...
Breaking Medicine Technology:Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... BEDFORD, Mass. , May 5 Instrumentation Laboratory (IL) today ... $586.4M USD ).  This represents 11.2% growth v. previous year in current, ... Critical Care and Hemostasis Diagnostics, worldwide growth in local currencies was 13.2% ... , "In ...
... May 5 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... The Ninth Annual JMP Securities Research Conference.  The Alexza presentation will be on ... presentation will be webcast from the Ritz Carlton Hotel in San Francisco ... To access the presentation via ...
Cached Medicine Technology:Instrumentation Laboratory Achieves Record Sales in 2009 2Instrumentation Laboratory Achieves Record Sales in 2009 3Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference 2Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference 3
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Pradaxa ... suffered serious, life-threatening episodes of internal bleeding while using the ... in U.S. District Court, Southern District of Illinois, Bernstein Liebhard ... website, 818 Pradaxa side effect claims had been ... That’s up from 705 claims reported by the Court on ...
(Date:5/25/2013)... orthodontists have thought about moving their office to the ... Most people would naturally assume that the company they'd ... and support would own and maintain all the physical ... wrong. Cloud providers lease space in a ... servers and related equipment to run cloud environments) owned ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the ... rate of 28.7% to $1.0 billion in the five years ... and 2008, no new cell therapy products were introduced, according ... during that period. In the years since, however, the Food ... factor contributed to the industry's fast growth during the five ...
(Date:5/25/2013)... 2013 Superior Magnetics for Pain Free ... seconds for arthritis, tendinitis and bursitis , Pain Free ... products announced a magnetic bracelet so strong ... pain relief is demonstrated at fairs and festivals. This ... magnets and has customers often report pain relief in ...
(Date:5/25/2013)... AdvantaClean of Pikes Peak recently opened and ... healthy home and business in Colorado Springs and surrounding ... inspections, mold testing, mold removal , air ... , With over 120 offices nationwide, AdvantaClean is a ... full suite of services for commercial, institutional, and governmental ...
Breaking Medicine News(10 mins):Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Magnetic bracelet relieves pain in seconds announces Superior Magnetics 2Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 2Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 3Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 4
... have discovered that mental and physical stimulation delays ... disease, Huntington,s disease. , This Australian research opens ... difficult to treat brain diseases, including Alzheimers disease ... The Floreys Dr Jess Nithianantharajah and Dr Anthony ...
... the font of all knowledge, despite the plethora of ... University of New South Wales (UNSW) in Australia have ... variety of useful materials, people pay more attention to ... people read the right material, they are stubborn to ...
... First test in country where disease is endemic produced ... A new malaria vaccine looked strong in a small ... researchers. , The vaccine -- designed to prevent the ... and provoked strong immune responses (up to a sixfold ...
... Fourteen Novalis Tx(TM) Orders Since September Launch Reinforce Strength of ... ... and MUNICH, Germany, Jan. 24 /PRNewswire-FirstCall/,-- Varian Medical Systems (NYSE: ... fourteen orders for the new Novalis Tx(TM),radiosurgical platform, which combines the ...
... 24 Proceeds will benefit Children,s,HeartLink (R) from Kim ... and February 29., "One in 100 children across ... third of those children will die before their first ... president, Children,s,HeartLink. "Kim & Scott,s commitment contributes to our ...
... Jan. 24 ZYTO Corp. (Pink Sheets:,ZYTC) has announced ... C.O.O., and Kami Howard as C.F.O., The internal ... 2008, according to Dr. Vaughn R. Cook, company founder, ... C.O.O. and handled the,financial responsibilities., Howard joined ZYTO ...
Cached Medicine News:Health News:Mental and physical exercise delays dementia in fatal genetic disease 2Health News:Why the Web tells us what we already know 2Health News:Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform 2Health News:Varian and BrainLAB Announce Rapid Uptake of Powerful and Versatile Radiosurgery Platform 3Health News:Children's HeartLink Benefits From Valentine's Day Love Knot Sampler Sales by Kim & Scott's Gourmet Pretzels 2Health News:ZYTO Corp. Appoints New Chief Operations Officer and New Chief Financial Officer 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: